Cargando…
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
BACKGROUND: More favorable treatment against epithelial ovarian cancer (EOC) is urgently needed because of its insidious nature at an early stage and a low rate of five-year survival. The current primary treatment, extensive surgery combined with chemotherapy, exhibits limited benefits for improving...
Autores principales: | Li, Tong, Wang, Jiandong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372885/ https://www.ncbi.nlm.nih.gov/pubmed/32689954 http://dx.doi.org/10.1186/s12885-020-07180-x |
Ejemplares similares
-
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
por: Mun, Sung Soo, et al.
Publicado: (2023) -
Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer
por: Jain, Shruti, et al.
Publicado: (2022) -
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
por: Sharma, Sai Kiran, et al.
Publicado: (2022) -
Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021) -
MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway
por: Zhang, Yinghui, et al.
Publicado: (2020)